Capital Raise

In mid-2024 we are raising AU$2m in equity capital to fund our 2 lead candidate antibodies through to the completion of in vivo testing for efficacy and toxicity. We invite expressions of interest from potential investors.

  • AUD $2m

  • AUD $200,000

  • Employ management team, optimize current candidates, implement patent strategy, complete animal testing for efficacy and toxicity, apply for grant funding.

  • Ordinary shares in Psaio Therapeutics Pty Ltd.

  • Discounted to AUD$15m for this offer – vs AUD$22m valuation in data room.

  • Family members and friends of co-founder shareholders will also participate in this Seed Capital Raise.

Private Capital 2024

Watch our 10 minute presentation from 21 May 2024 at the Private Capital 2024 investor conference in Sydney.